https://www.selleckchem.com/pr....oducts/Vorinostat-sa
Down syndrome (DS) is an independent risk factor for severe respiratory syncytial virus (RSV) infection. Palivizumab - passive immunization for RSV - is the only pharmacological measure for preventing severe disease. In most countries, palivizumab is indicated in young children with congenital heart disease, premature birth, and chronic lung disease. In Japan, since 2013, children with DS, but without such "standard" risk factors, have been able to receive insurance-covered palivizumab prophylaxis, but its effectiveness of polic
Like
Comment
Share
